QIAGEN N.V. (QGEN) has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the company’s second FDA clearance of a QIAstat-Dx panel in 2025, building on the authorization of five panels for use on the QIAstat-Dx system in the last 10 months.With the latest development, QIAGEN now has regulatory clearances for three mini panels for the detection of respiratory and gastrointestinal conditions. Th ...